Adam Cuker, MD, on Higher Efficacy of Gene Therapy Over SOC in Hemophilia B

Video

The associate professor of medicine at University of Pennsylvania discussed new data from the BENEGENE-2 study of fidanacogene elaparvovec.

“I think fidanacogene elaparvovec is promising for a couple of reasons. We see that with a single infusion there was superiority to standard-of-care in reducing bleeds, and there were no worrisome safety signals that emerged. This appeared to be a durable response over 24 months, but of course, longer-term follow-up is needed. We hope for, essentially, a cure for hemophilia with gene therapy. And based on these results, preliminary though they are, they're a very encouragingstep toward that goal.”

A single infusion treatment of fidanacogeneelaparvovec demonstrated superiority over standard-of-care factor IX therapy in reducing annualized bleeding rates (ABR) in patients with hemophilia B, according to updated data from Pfizer’s BENEGENE-2 phase 3 clinical trial (NCT03861273). Compared with a 6-month lead-in period, patients treated with the therapy had a 78% reduction in ABR for treated bleeds (P = .0001)and a 92% reduction in the annualized infusion rate of exogenous FIX following infusion with fidanacogene elaparvovec (P <.0001).

CGTLive spoke with study investigator Adam Cuker, MD, associate professor of medicine, University of Pennsylvania, to learn more about BENEGENE-2 and the new superiority data. He also touched on the positive durability data seen in patients treated with fidanacogeneelaparvovec.

REFERENCE
Pfizer announces positive top-line results from phase 3 study of hemophilia B gene therapy candidate. News release. Pfizer. December 20, 2023. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study
Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.